Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Sample Collection
2.3. Digital Droplet Polymerase Chain Reaction (ddPCR)
2.4. Clinicopathological Data Collection and Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Available online: https://www.iarc.fr/featured-news/media-centre-iarc-news-wcd (accessed on 2 February 2017).
- del Carmen, M.G.; Schorge, J.O. Invasive Cervical Adenocarcinoma; UpToDate: Waltham, MA, USA, 2019. [Google Scholar]
- Wang, S.S.; Hildesheim, A. Chapter 5: Viral and host factors in human papillomaviruspersistence and progression. JNCI Monogr. 2003, 31, 35–40. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ojesina, A.I.; Lichtenstein, L.; Freeman, S.S.; Pedamallu, C.S.; Imaz-Rosshandler, I.; Pugh, T.J.; Cherniack, A.D.; Ambrogio, L.; Cibulskis, K.; Bertelsen, B.; et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014, 506, 371–375. [Google Scholar] [CrossRef] [PubMed]
- Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 2017, 543, 378–384. [Google Scholar] [CrossRef] [PubMed]
- Halle, M.K.; Ojesina, A.I.; Engerud, H.; Woie, K.; Tangen, I.L.; Holst, F.; Høivik, E.; Kusonmano, K.; Haldorsen, I.S.; Vintermyr, O.K.; et al. Clinicopathologic and molecular markers in cervical carcinoma: A prospective cohort study. Am. J. Obstet. Gynecol. 2017, 217, 432.e1–432.e17. [Google Scholar] [CrossRef] [PubMed]
- Lachkar, B.; Minaguchi, T.; Akiyama, A.; Liu, S.; Zhang, S.; Xu, C.; Shikama, A.; Tasaka, N.; Sakurai, M.; Nakao, S.; et al. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Med. Baltim. 2018, 97, e11392. [Google Scholar] [CrossRef] [PubMed]
- Chung, T.K.H.; Van Hummelen, P.; Chan, P.K.S.; Cheung, T.H.; Yim, S.F.; Yu, M.Y.; Ducar, M.D.; Thorner, A.R.; MacConaill, L.E.; Doran, G.; et al. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int. J. Cancer 2015, 136, 776–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, T.K.H.; Cheung, T.H.; Yim, S.F.; Thorner, A.R.; Ducar, M.D.; Lau, K.K.M.; Wong, R.R.Y.; Berkowitz, R.S.; Wong, Y.F. Recurrent mutations and liquid biopsy in cervical adenocarcinoma. In Proceedings of the Second AACR International Conference: Translational Cancer Medicine, Cancer Discoveries for Clinical Application, Sao Paulo, Brazil, 27–29 September 2018; p. B45. [Google Scholar]
- Ligresti, G.; Militello, L.; Steelman, L.S.; Cavallaro, A.; Basile, F.; Nicoletti, F.; Stivala, F.; McCubrey, J.A.; Libra, M. PIK3CA mutations in human solid tumors. Cell Cycle 2009, 8, 1352–1358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McIntyre, J.B.; Wu, J.S.; Craighead, P.S.; Phan, T.; Köbel, M.; Lees-Miller, S.P.; Ghatage, P.; Magliocco, A.M.; Doll, C.M. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol. Oncol. 2014, 128, 409–414. [Google Scholar] [CrossRef] [PubMed]
- Wright, A.A.; Howitt, B.E.; Myers, A.P.; Dahlberg, S.E.; Palescandolo, E.; van Hummelen, P.; MacConaill, L.E.; Shoni, M.; Wagle, N.; Jones, R.T.; et al. Oncogenic mutations in cervical cancer: Enomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013, 119, 3776–3783. [Google Scholar] [CrossRef] [PubMed]
- Xiang, L.; Li, J.; Jiang, W.; Shen, X.; Yang, W.; Wu, X.; Yang, H. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget 2015, 6, 4968–4975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xiang, L.; Jiang, W.; Li, J.; Shen, X.; Yang, W.; Yang, G.; Wu, X.; Yang, H. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci. Rep. 2015, 5, 14035. [Google Scholar] [CrossRef] [PubMed]
- Akbarov, K.; Isayev, I.; Melikova, L.; Guliyev, E.; Aliyeva, N. PIK3CA gene mutation frequency among cervical cancer patients in Azerbajian. Ann. Oncol. 2017, 28 (Suppl. S10), 86–93. [Google Scholar]
- Hodgson, A.; Amemiya, Y.; Seth, A.; Cesari, M.; Djordjevic, B.; Parra-Herran, C. Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: Biologic and clinical implications. Mod. Pathol. 2017, 30, 1633–1641. [Google Scholar] [CrossRef] [PubMed]
- Razia, S.; Nakayama, K.; Nokamura, K.; Ishibashi, T.; Ishikawa, M.; Minamoto, T.; Iida, K.; Otsuki, Y.; Nakayama, S.; Ishikawa, N. Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. Exp. Ther. Med. 2019, 18, 2278–2284. [Google Scholar] [CrossRef] [Green Version]
- Scholl, S.; Popovic, M.; de la Rochefordiere, A.; Girard, E.; Dureau, S.; Mandic, A.; Koprivsek, K.; Samet, N.; Craina, M.; Margan, M.; et al. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine 2019, 43, 253–260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arafeh, R.; Samules, Y. PIK3CA in caner: The past 30 years. Semin. Cancer Biol. 2019, 59, 36–49. [Google Scholar] [CrossRef] [PubMed]
- Papadimitrakopoulou, V.A.; Han, J.; Ahn, M.; Ramalingam, S.S.; Delmonte, A.; Hsia, T.; Laskin, J.; Kim, S.; He, Y.; Tsai, C.; et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non–small cell lung cancer. Cancer 2020, 126, 373–380. [Google Scholar] [CrossRef] [PubMed]
- Hrebien, S.; Citi, V.; Garcia-Murillas, I.; Cutts, R.; Fenwick, K.; Kozarewa, I.; McEwen, R.; Ratnayake, J.; Maudsley, R.; Carr, T.H.; et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann. Oncol. 2019, 30, 945–952. [Google Scholar] [CrossRef] [PubMed]
- Yang, B.; Zhang, W.; Zhang, M.; Wang, X.; Peng, S.; Zhang, R. KRT6A Promotes EMT and Cancer Stem Cell Transformation in Lung Adenocarcinoma. Technol. Cancer Res. Treat. 2020, 19, 15330338209212. [Google Scholar] [CrossRef] [PubMed]
Case | Code | Age | Stage | Grade | Size | LN | LVSI | Recur | Status | S/F Time | p16 | HPV Genotype |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | C1062 | 47 | IB1 | 2 | 2 | (−) | n/a | (−) | Alive | 55 | n/a | Undetected |
2 | C1071 | 35 | IB2 | 3 | 4 | n/a | (+) | (−) | Alive | 58 | (−) | Undetected |
3 | C1072 | 49 | IB2 | 1 | 1 | n/a | (−) | n/a | Alive | 2 | (−) | HPV18 |
4 | C1074 | 63 | IB1 | 3 | 2 | (−) | (−) | (−) | Alive | 56 | (−) | HPV18 |
5 | C1080 | 35 | IB1 | 2 | 3 | (−) | (−) | (+) | Alive | 47 | n/a | HPV18 |
6 | C1082 | 75 | IIB | 2 | 4 | (+) | (+) | (+) | Died | 39 | (+) | HPV52 |
7 | C1084 | 38 | IB1 | 2 | 3 | (−) | (−) | (+) | Died | 46 | n/a | HPV16 |
8 | C1094 | 54 | IB2 | 2 | 1 | n/a | n/a | (−) | Alive | 50 | (+) | HPV18 |
9 | C1106 | 53 | IV | 2 | 5 | n/a | n/a | (+) | Died | 36 | n/a | HPV18 |
10 | C1108 | 43 | IB1 | 2 | 1 | (−) | (−) | (−) | Alive | 47 | (+) | HPV16 |
11 | C1112 | 57 | IB1 | 3 | 2 | (−) | (−) | (+) | Alive | 44 | (+) | HPV18 |
12 | C1119 | 43 | IIB | 2 | 4 | n/a | n/a | (−) | Alive | 41 | (+) | HPV18 |
13 | C1126 | 71 | IIB | 2 | 4 | n/a | n/a | (+) | Died | 13 | n/a | Undetected |
14 | C1128 | 34 | IIB | 2 | 1 | n/a | (−) | n/a | Alive | 1 | (+) | HPV18 |
15 | C1129 | 42 | IIB | 2 | 2 | n/a | (−) | (−) | Alive | 30 | (+) | HPV18 |
16 | C1135 | 40 | IV | 2 | 1 | n/a | (+) | (+) | Died | 26 | n/a | Undetected |
17 | C1136 | 46 | IB1 | 2 | 1 | (−) | (−) | (−) | Alive | 37 | (+) | HPV16 |
18 | C1138 | 49 | IB1 | 2 | 1 | (−) | (−) | (−) | Alive | 37 | (+) | HPV16 |
19 | C1165 | 55 | IB1 | 3 | 1 | (−) | (−) | (−) | Alive | 25 | n/a | HPV18 |
20 | C1169 | 48 | IB2 | 2 | 1 | (−) | (−) | (−) | Alive | 24 | (+) | HPV16 |
21 | C1172 | 57 | IB1 | 2 | 2 | (−) | (−) | (−) | Alive | 24 | (+) | Undetected |
22 | C1177 | 57 | IB1 | 2 | 3 | (−) | (−) | (−) | Alive | 17 | n/a | HPV18 |
23 | C1181 | 37 | IB1 | 2 | 1 | n/a | n/a | (−) | Alive | 22 | (+) | HPV45 |
24 | C1187 | 51 | IB2 | 2 | 3 | (+) | (+) | (−) | Alive | 20 | n/a | HPV16 |
Features and SNV Mutations | PFS | OS | ||
---|---|---|---|---|
p Value | Hazard Ratio | p Value | Hazard Ratio | |
Age (Grouped) (Year) 1 ≤ 50 2 > 50 | 0.2681 | 0.3860 | 0.2872 | 0.3943 |
Stage (Grouped) FIGO staging 1 = stage IA-IIA 2 = stage IIB-IV | 0.0036 | 12.2162 | 0.0007 | 15.2896 |
Grade (Grouped) WHO grading 1 = grade1,2 2 = grade3 | 0.5356 | n/a | n/a | n/a |
Tumor size (cm) | 0.0784 | n/a | 0.2051 | n/a |
Pelvic LN metastasis | 0.1284 | 6.4667 | 0.0143 | 13.0000 |
LVSI | 0.1838 | 4.3955 | 0.2448 | 3.7600 |
Recurrence | 0.0001 | n/a | 0.0026 | n/a |
P16 | 0.5637 | n/a | 0.5271 | n/a |
HPV | 0.2156 | 0.3443 | 0.3057 | 0.4069 |
PIK3CA—T | 0.6505 | 1.5000 | 0.8171 | 1.2340 |
PIK3CA—B | 0.0291 | 7.7068 | 0.0499 | 6.6105 |
PIK3CA—F | 0.0679 | n/a | 0.0429 | n/a |
KRAS—T | 0.4792 | 2.1376 | 0.4792 | 2.1376 |
KRAS—B | n/a | n/a | n/a | n/a |
KRAS—F | 0.5202 | n/a | 0.4183 | n/a |
KRT6A—T | 0.3978 | 0.4762 | 0.5151 | 0.5579 |
KRT6A—B | 0.8829 | 0.8501 | n/a | n/a |
KRT6A—F | 0.4448 | 0.4067 | 0.7033 | 0.6299 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chung, T.K.H.; Doran, G.; Cheung, T.-H.; Yim, S.-F.; Yu, M.-Y.; Worley, M.J., Jr.; Elias, K.M.; Thorner, A.R.; Pedamallu, C.S.; Ojesina, A.I.; et al. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers 2021, 13, 3218. https://doi.org/10.3390/cancers13133218
Chung TKH, Doran G, Cheung T-H, Yim S-F, Yu M-Y, Worley MJ Jr., Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, et al. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers. 2021; 13(13):3218. https://doi.org/10.3390/cancers13133218
Chicago/Turabian StyleChung, Tony K. H., Graeme Doran, Tak-Hong Cheung, So-Fan Yim, Mei-Yung Yu, Michael J. Worley, Jr., Kevin M. Elias, Aaron R. Thorner, Chandra Sekhar Pedamallu, Akinyemi I. Ojesina, and et al. 2021. "Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes" Cancers 13, no. 13: 3218. https://doi.org/10.3390/cancers13133218